Key Points
- Insider selling: Sharon Benzeno sold 12,604 shares on Dec. 4 at $16.85 for $212,377 (a 4.07% stake reduction) and had earlier sold 297,925 and 308,477 shares on Nov. 20–21 (approximately $10.14M combined), per the SEC filing.
- Revenue beat but unprofitable: Adaptive reported Q3 revenue of $93.97M (up 102.4% YoY) and EPS of ($0.15) beating estimates, yet the company remains unprofitable with negative margins and analysts expect ~-0.92 EPS for the year.
- Analyst sentiment and stock metrics: Several firms raised targets to $20–21 and the consensus is a "Moderate Buy" with a $17.11 target; the stock trades in a 12‑month range of $5.80–$20.76, market cap ~$2.28B and a negative P/E.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Sharon Benzeno sold 12,604 shares of the business's stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $16.85, for a total transaction of $212,377.40. Following the transaction, the insider owned 296,791 shares in the company, valued at $5,000,928.35. This represents a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Sharon Benzeno also recently made the following trade(s):
- On Thursday, November 20th, Sharon Benzeno sold 297,925 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.54, for a total transaction of $4,927,679.50.
- On Friday, November 21st, Sharon Benzeno sold 308,477 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.91, for a total value of $5,216,346.07.
Adaptive Biotechnologies Stock Up 1.4%
NASDAQ:ADPT opened at $14.95 on Tuesday. Adaptive Biotechnologies Corporation has a 12-month low of $5.80 and a 12-month high of $20.76. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -27.68 and a beta of 2.20. The stock's 50 day moving average price is $16.39 and its two-hundred day moving average price is $13.29.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same period in the previous year, the company posted ($0.22) EPS. The firm's revenue for the quarter was up 102.4% compared to the same quarter last year. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an "overweight" rating in a report on Wednesday, October 15th. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a "buy" rating and a $20.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. BTIG Research boosted their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an "overweight" rating in a research report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of "Moderate Buy" and a consensus target price of $17.11.
Read Our Latest Stock Report on Adaptive Biotechnologies
Institutional Trading of Adaptive Biotechnologies
Institutional investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. bought a new position in shares of Adaptive Biotechnologies during the third quarter worth approximately $238,000. Harvest Investment Services LLC grew its position in Adaptive Biotechnologies by 104.7% during the third quarter. Harvest Investment Services LLC now owns 344,512 shares of the company's stock worth $5,154,000 after buying an additional 176,235 shares in the last quarter. Oberweis Asset Management Inc. increased its stake in Adaptive Biotechnologies by 23.3% during the 3rd quarter. Oberweis Asset Management Inc. now owns 726,500 shares of the company's stock worth $10,868,000 after acquiring an additional 137,100 shares during the period. Castleark Management LLC bought a new position in Adaptive Biotechnologies during the 3rd quarter worth $4,459,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Adaptive Biotechnologies by 17.6% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 30,469 shares of the company's stock valued at $456,000 after acquiring an additional 4,552 shares in the last quarter. Institutional investors own 99.17% of the company's stock.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
